Cure versus failure/relapse for high-dose gatifloxacin-based treatment stratified by MIC values; only one pre-MDR-treatment isolate per patient included
| GAT MIC (mg/L) . | Failure/relapse . | Cure . | Total . | Percentage cured . | OR to fail . | 95% CI . |
|---|---|---|---|---|---|---|
| ≤0.25 | 3 | 84 | 87 | 96.6 | 1 | |
| 0.5 | 1 | 17 | 18 | 94.4 | 1.6 | 0.16–16.8 |
| 1 | 3 | 14 | 17 | 82.4 | 6.0 | 1.1–32.8 |
| 2 | 7 | 9 | 16 | 56.3 | 21.8 | 4.8–99.3 |
| 4 | 8 | 7 | 15 | 46.7 | 32.0 | 6.9–148.5 |
| 8 | 5 | 0 | 5 | 0.0 | undef | |
| >8 | 3 | 0 | 3 | 0.0 | undef | |
| Total | 30 | 131 | 161 | 81.4 |
| GAT MIC (mg/L) . | Failure/relapse . | Cure . | Total . | Percentage cured . | OR to fail . | 95% CI . |
|---|---|---|---|---|---|---|
| ≤0.25 | 3 | 84 | 87 | 96.6 | 1 | |
| 0.5 | 1 | 17 | 18 | 94.4 | 1.6 | 0.16–16.8 |
| 1 | 3 | 14 | 17 | 82.4 | 6.0 | 1.1–32.8 |
| 2 | 7 | 9 | 16 | 56.3 | 21.8 | 4.8–99.3 |
| 4 | 8 | 7 | 15 | 46.7 | 32.0 | 6.9–148.5 |
| 8 | 5 | 0 | 5 | 0.0 | undef | |
| >8 | 3 | 0 | 3 | 0.0 | undef | |
| Total | 30 | 131 | 161 | 81.4 |
GAT, gatifloxacin; undef, undefined.
Cure versus failure/relapse for high-dose gatifloxacin-based treatment stratified by MIC values; only one pre-MDR-treatment isolate per patient included
| GAT MIC (mg/L) . | Failure/relapse . | Cure . | Total . | Percentage cured . | OR to fail . | 95% CI . |
|---|---|---|---|---|---|---|
| ≤0.25 | 3 | 84 | 87 | 96.6 | 1 | |
| 0.5 | 1 | 17 | 18 | 94.4 | 1.6 | 0.16–16.8 |
| 1 | 3 | 14 | 17 | 82.4 | 6.0 | 1.1–32.8 |
| 2 | 7 | 9 | 16 | 56.3 | 21.8 | 4.8–99.3 |
| 4 | 8 | 7 | 15 | 46.7 | 32.0 | 6.9–148.5 |
| 8 | 5 | 0 | 5 | 0.0 | undef | |
| >8 | 3 | 0 | 3 | 0.0 | undef | |
| Total | 30 | 131 | 161 | 81.4 |
| GAT MIC (mg/L) . | Failure/relapse . | Cure . | Total . | Percentage cured . | OR to fail . | 95% CI . |
|---|---|---|---|---|---|---|
| ≤0.25 | 3 | 84 | 87 | 96.6 | 1 | |
| 0.5 | 1 | 17 | 18 | 94.4 | 1.6 | 0.16–16.8 |
| 1 | 3 | 14 | 17 | 82.4 | 6.0 | 1.1–32.8 |
| 2 | 7 | 9 | 16 | 56.3 | 21.8 | 4.8–99.3 |
| 4 | 8 | 7 | 15 | 46.7 | 32.0 | 6.9–148.5 |
| 8 | 5 | 0 | 5 | 0.0 | undef | |
| >8 | 3 | 0 | 3 | 0.0 | undef | |
| Total | 30 | 131 | 161 | 81.4 |
GAT, gatifloxacin; undef, undefined.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
